ArticlePituitary2026
Early postoperative LDDST enhances remission prediction beyond morning cortisol in cushing's disease.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTranssphenoidal surgery (TSS) is the recommended treatment for Cushing's disease (CD). While low morning serum cortisol (MSeC) indicates early remission, the predictive value of an early postoperative overnight 2 mg low-dose dexamethasone suppression test (LDDST) remains unclear. This study compares the accuracy of early postoperative MSeC and LDDST for predicting early and long-term remission after TSS.
methodsWe retrospectively analysed 342 CD surgical cases, who underwent TSS in our department between 2004 and 2024. Morning cortisol measurements were obtained postoperatively. An overnight 2 mg LDDST was performed on postoperative day five, in selected cases, preferentially in those without immediate postoperative biochemical remission (MSeC > 50 nmol/L), rather than as a universal screening test.
resultsImmediate postoperative biochemical remission (IPBR; MSeC < 50 nmol/L) was achieved in 170 cases (49.7%). LDDST was performed in 197 cases (57.6%), with complete suppression (< 50 nmol/L) in 137 (69.5%). Remission at first follow-up (3-6 months) was significantly higher in cases with IPBR (99.4%) and/or complete LDDST suppression (98.5%) compared to those without (45.0%; p < .0001*). Long-term remission also correlated significantly with postoperative MSeC and LDDST (p < .0001*). ROC analyses confirmed strong predictive accuracy for remission during first FU (AUC MSeC: 0.9229; LDDST: 0.9413) and long-term (AUC MSeC: 0.8267; LDDST: 0.8058). Five-year recurrence risk was 71.1% without LDDST suppression versus 6.8% with suppression.
conclusionEarly postoperative MSeC and LDDST are reliable predictors of remission after TSS in CD. MSeC < 50 nmol/L safely define biochemical remission. LDDST adds diagnostic value, particularly in cases with borderline, normal or elevated MSeC, and should be included in routine postoperative assessment.
Indexed as
Identifiers
41663683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.